Non-cystic fibrosis bronchiectasis: An evidence-base for new therapies

The Lancet Respiratory Medicine

Volumn 2, Issue 12, 2014, Pages 958-960

  Bilton, Diana ^a,b   Loebinger, Michael R ^a,b   Wilson, Robert ^a,b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; AZTREONAM LYSINE; COLISTIN; MACROLIDE; MANNITOL; PLACEBO; ANTIINFECTIVE AGENT;

BACTERIAL LOAD; BRONCHIECTASIS; BRONCHIECTASIS SEVERITY SCORE; DISEASE EXACERBATION; FACED SCORE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; MORTALITY; MUCOCILIARY CLEARANCE; NONCYSTIC FIBROSIS BRONCHIECTASIS; NOTE; PATIENT COMPLIANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; EVIDENCE BASED MEDICINE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX;

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; EVIDENCE-BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMANS; MUCOCILIARY CLEARANCE; PRACTICE GUIDELINES AS TOPIC; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 84919657900     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70274-7     Document Type: Note

References (10)

1. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guidelines for non-CF bronchiectasis. Thorax 2010, 65:i1-58.
2. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med 2014, 189:576-585.
3. Martínez-García MA, deGracia J, Vendrell-Relat M, et al. Multi-dimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014, 43:1357-1367.
4. Haworth CS, Bilton D, Elborn S Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med 2014, 108:1397-1408.
5. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014, published Sept 21. 10.1136/thoraxjnl-2014-205587.
6. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase 2 randomised study. Eur Respir J 2013, 41:1107-1115.
7. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014, 189:975-982.
8. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014, 2:738-749.
9. Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014, 2:455-463.
10. Rowan SA, Bradley JM, Bradbury I, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med 2014, 189:586-592.